Oncology Medical News

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09

Kenter GG et al. – Clinical responses in women with HPV-16–positive, grade 3 vulvar intraepithelial neoplasia can be achieved by vaccination with a synthetic long-peptide vaccine against the HPV-16 oncoproteins E6 and E7. Complete responses appear to be correlated with induction of HPV-16–specific immunity.

Methods

Immunogenicity and efficacy of a synthetic long-peptide vaccine in women with HPV-16–positive, high-grade vulvar intraepithelial neoplasia investigated
20 women with HPV-16–positive, grade 3 vulvar intraepithelial neoplasia vaccinated 3 or 4 times with mix of long peptides from HPV-16 viral oncoproteins E6 and E7 in incomplete Freund's adjuvant
End points were clinical and HPV-16–specific T-cell responses

Results

Most common adverse events were local swelling in 100% of patients and fever in 64% of patients
No events exceeded grade 2 of the Common Terminology Criteria for Adverse Events of the National Cancer Institute
At 3 months after last vaccination, 12 of 20 patients (60%; 95% confidence interval [CI], 36 to 81) had clinical responses and reported relief of symptoms
5 women had complete regression of lesions, and HPV-16 was no longer detectable in 4 of them
At 12 months of follow-up, 15 of 19 patients had clinical responses (79%; 95% CI, 54 to 94), with complete response in 9 of 19 patients (47%; 95% CI, 24 to 71)
Complete-response rate maintained at 24 months of follow-up
All patients had vaccine-induced T-cell responses, and post hoc analyses suggested that patients with a complete response at 3 months had a significantly stronger interferon-&Upsilon–associated proliferative CD4+ T-cell response and a broad response of CD8+ interferon-&Upsilon- T cells than did patients without a complete response

<< Previous
Activity of fulvestrant in HER2-overexpressing advanced breast...

Next >>
Phase II study of oxaliplatin plus S-1 as first-line treatment...